Key regions: Australia, Italy, France, South Korea, Brazil
The healthcare industry in Rwanda has been growing rapidly over the past few years, with the government investing heavily in improving the healthcare infrastructure and services. As a result, the vaccines market in Rwanda has also been growing steadily, driven by increasing demand for immunization services and government initiatives to improve access to vaccines.
Customer preferences: Customers in Rwanda are becoming increasingly aware of the importance of vaccination in preventing diseases and are more willing to take preventive measures to protect themselves and their families. This has led to a growing demand for vaccines, particularly for children under the age of five who are most vulnerable to infectious diseases.
Trends in the market: The vaccines market in Rwanda is characterized by a growing demand for new and innovative vaccines, particularly those that target diseases that are prevalent in the region. There has been a significant increase in the use of vaccines for diseases such as pneumococcal disease, rotavirus, and human papillomavirus (HPV), which are major causes of morbidity and mortality in the country.
Local special circumstances: Rwanda has a relatively small population, which makes it easier for the government to implement vaccination programs and reach a larger proportion of the population. The government has also been proactive in introducing new vaccines and expanding the immunization schedule to cover more diseases. This has helped to increase the demand for vaccines and improve vaccination coverage rates in the country.
Underlying macroeconomic factors: The Rwandan government has made significant investments in the healthcare sector over the past few years, which has helped to improve access to healthcare services and increase demand for vaccines. The country has also made progress in improving its healthcare infrastructure, including the construction of new hospitals and clinics, which has helped to expand the reach of vaccination programs. Additionally, the government has implemented policies to support the local pharmaceutical industry, which has helped to increase the availability of vaccines in the country.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
